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viral infections or malignancies. These results rely on prospectively col-
lected registry data that might be skewed by reporting bias and correla-
tions do not necessarily prove causality. Nonetheless, this observation
ﬁts well into the increasingly recognized role of NK cells in adaptive
immunity.Common variable immunodeﬁciency (CVID)
NK cellsNatural Killer (NK) cells were described 40 years ago as lymphoid
cells exerting cytolytic activity against tumor cell lines in vitro
(Herberman et al., 1975) and are accounted to the group of innate lym-
phoid cells. Functionally, they have been associated with anti-viral im-
munity (esp. herpesviridae) and tumor surveillance. However, NK
cells have been less in the research focus compared to other compo-
nents of the immune system (citations in Pubmed in 2015: ~2600 for
NK cells compared to ~7100, ~14,600 and ~12,100 for B, T cells and
macrophages, respectively). An isolated reduction of NK cells in humans
has been suggested to be asymptomatic.Whether this notion somewhat
reﬂects the inattentiveness towards NK cells or if NK cells in humans
have only redundant functions in the immune system is still a matter
of debate.
Eric Vivier and colleagues hypothesized that the function of NK cells
in humans might be revealed in immunocompromised subjects and re-
port on a large cohort of patients with common variable immunodeﬁ-
ciency (CVID) registered in the French Registry (DEFI) (Ebbo et al.,
2016). They stratiﬁed 457 CVID patients according to their NK cell num-
bers at study inclusion: roughly half of the patients had normal NK cell
counts (N100/μl), one quarter of the patients had slightly reduced NK
cell counts (50–99/μl) and almost one quarter had severely reduced
NK cell numbers (b50/μl). CVID patients with severe NK cell lymphope-
nia exhibited a statistically signiﬁcant increased rate of invasive bacteri-
al infections deﬁned as septicemia, pneumonia or meningitis: the
frequency of invasive infections was 68.7% in severe NK lymphopenia,
60.2% in mild NK lymphopenia and 48.8% in patients with normal NK
cell counts. However, there was no correlation of NK cell number andm.2016.02.025.
. This is an open access article underApart from insights into NK cell biology the paper by Ebbo et al. re-
veals interesting aspects of NK cells in CVID. On a clinical basis CVID pa-
tients can be separated into patients who suffer from infectious
complications as only complaint (“infection-only group”) and those
who additionally suffer from non-infectious complications/immune
dysregulation with e.g. lymphoproliferation, lung disease, enteropathy
andmalignancies. Whilst the infection-only group has a close to normal
life expectancy when treated with immunoglobulin replacement, pa-
tients with immune dysregulation have an elevated mortality (Resnick
et al., 2012). It is therefore of crucial interest to identify these patients
early in the course of the disease and multiple groups have attempted
to identify biomarkers in CVID by different approaches targeting B
and/or T cells in the majority of cases (Piqueras et al., 2003;
Giovannetti et al., 2007; Moratto et al., 2006; Driessen et al., 2011;
Kamae et al., 2013; Wehr et al., 2008; Chapel et al., 2012). Ebbo and
co-workers now add NK cells as a potential biomarker to the list as
they showed that CVID patients with non-infectious complications are
overrepresented amongst the patients with severe NK lymphopenia.
This was signiﬁcant for patients with granulomatous complications
(NK cells severely reduced vs mildly reduced vs normal: 25.3% vs
13.6% vs 8.8%, p b 0.001) but there was also a trend towards higher fre-
quencies of lymphoid hyperplasia (35.4% vs 24.6% and 19.2%), enterop-
athies (41.4% vs 28% vs 24.2%) and autoimmune cytopenia (25.3% vs
12.7% vs 14.6%). The authors also report that severely reduced NK cell
counts in CVID are associated with lymphopenia i.e. CD4+ lymphope-
nia (median 415/μl vs 568 and 691/μl, p = 0.003), reduction of naïve
CD4+ cells (median 63/μl vs 135 and 183/μl, p = 0.003), CD8 lympho-
penia (310/μl vs 431/μl vs 479/μl, p = 0.003) and B lymphopenia (me-
dian: 59/μl vs 99/μl and 122/μl, p = 0.003). CVID patients with severe
NK lymphopenia also had lower levels of IgG, A andM at initial diagno-
sis compared to the two other groups. Mortality was higher in CVID
with low T cell numbers (T cells b200/μl) but not in patients with isolat-
ed lowNK lymphopenia.Whilst other groups have associated low naïve
CD4 cell counts and expansion of CD21low B cells with a more severe
CVID phenotype, Ebbo et al. show a weak, positive correlation between
NK cell counts and CD21low B cells (r = 0.13, p = 0.05).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
19C. Wehr / EBioMedicine 6 (2016) 18–19Considering the large CVID cohort investigated by Ebbo et al., NK
cells will have to be considered in future attempts to stratify CVID pa-
tients. Ideally the topic will be approached by a multinational team to
unify the multiple attempts and dissect predictive biomarkers in CVID
helping to early identify patients at risk from severe manifestations.
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